Drug the Undruggable Technologies

Nov 2022

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

2.350,00€

Mar 2022

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

2.450,00€

Oct 2021

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

2.250,00€

May 2020

Report Package: “Drug the Undruggable” Technologies

8.250,00€

4.125,00€

May 2020

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

2.050,00€

Sep 2019

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

2.050,00€

May 2018

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

4.450,00€

2.670,00€

May 2018

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

2.150,00€

Jan 2018

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

2.300,00€

2.000,00€

Report categories

Antibody & Protein Sales

Antibody Technologies

Biosimilar Antibodies & Proteins

Drug the Undruggable Technologies

Immuno-Oncology

mRNA Vaccines & Therapeutics

NK Cells & CAR Macrophages

Pipeline Database

RNA-Targeted Therapeutics

Target Pipelines

TCR T-Cells and Antibodies

Therapeutic Antibodies

Therapeutic Proteins & Peptides